Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation

Background: The long-term risk of thrombotic and vascular complications is elevated in liver transplant recipients compared to the general population. Patients with cirrhosis are in a hypercoagulable status during and directly after orthotopic liver transplantation, but it is unclear whether this hypercoagulability persists over time. Aim: We aimed to investigate the hemostatic status of liver transplant recipients one year after transplantation. Methods: We prospectively collected blood samples of 15 patients with a functioning graft one year after orthotopic liver transplantation and compared the hemostatic status of these patients with that of 30 healthy individuals. Results: Patients one year after liver transplantation had significantly elevated plasma levels of von Willebrand factor (VWF). Thrombin generation, as assessed by the endogenous thrombin potential, was decreased in patients, which was associated with increased plasma levels of the natural anticoagulants antithrombin and tissue factor pathway inhibitor. Plasma fibrinolytic potential was significantly decreased in patients and correlated inversely with levels of plasminogen activator inhibitor-1. Conclusion: One year after liver transplantation, liver graft recipients have a dysregulated hemostatic system characterised by elevation of plasma levels of endothelial-derived proteins. Increased levels of von Willebrand factor and decreased fibrinolytic potential may (in part) be responsible for the increased risk for vascular disease seen in liver transplant recipients.

[1]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[2]  I. T. Ten Berge,et al.  Treatment with everolimus is associated with a procoagulant state. , 2013, Thrombosis research.

[3]  R. Porte,et al.  Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[4]  D. Brieger,et al.  Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. , 2013, Thrombosis research.

[5]  R. Porte,et al.  Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.

[6]  F. Rosendaal,et al.  Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. , 2010, Blood.

[7]  R. Porte,et al.  Intact thrombomodulin‐mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulin‐mediated regulation of coagulation , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  J. Rosing,et al.  Thrombin generation‐based assays to measure the activity of the TFPI–protein S pathway in plasma from normal and protein S‐deficient individuals , 2010, Journal of thrombosis and haemostasis : JTH.

[9]  R. Porte,et al.  Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. , 2010, Journal of hepatology.

[10]  M. Senzolo,et al.  Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[11]  Johnny C. Hong,et al.  Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. , 2009, Journal of the American College of Surgeons.

[12]  R. Porte,et al.  Development of a Severe von Willebrand Factor/ADAMTS13 Dysbalance During Orthotopic Liver Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  E. Horváth-Puhó,et al.  Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study , 2009, The American Journal of Gastroenterology.

[14]  M. J. Fabiá,et al.  [Venous thromboembolism and liver cirrhosis]. , 2008, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[15]  F. Rosendaal,et al.  Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis , 2008, PLoS medicine.

[16]  N. Chalasani,et al.  Deep Vein Thrombosis and Pulmonary Embolism in Cirrhosis Patients , 2008, Digestive Diseases and Sciences.

[17]  R. van Oerle,et al.  Coagulation factors and the protein C system as determinants of thrombin generation in a normal population , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  W. Sluiter,et al.  Vascular events after liver transplantation: a long‐term follow‐up study , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  M. Vivarelli,et al.  Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  S. Caldwell,et al.  Coagulopathy Does Not Fully Protect Hospitalized Cirrhosis Patients from Peripheral Venous Thromboembolism , 2006, The American Journal of Gastroenterology.

[21]  Yoshihiro Kokubo,et al.  FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.

[22]  A. Tripodi,et al.  Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests , 2005, Hepatology.

[23]  F. Rosendaal,et al.  Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. , 2004, Blood.

[24]  A. Folsom,et al.  Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). , 2002, The American journal of medicine.

[25]  M. Carrier,et al.  Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  P. D. de Groot,et al.  Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation , 2002, Hepatology.

[27]  M. Picard,et al.  Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. , 2001, Transplantation.

[28]  T. Rabelink,et al.  Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation. , 2001, The Netherlands journal of medicine.

[29]  J. McMurray,et al.  Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. , 2000, Kidney international.

[30]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[31]  T. Nilsson,et al.  von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction , 1998, Heart.

[32]  B. Meiser,et al.  Impact of immunosuppression on coronary endothelial function after cardiac transplantation. , 1998, Transplantation proceedings.

[33]  D. Dunn,et al.  Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. , 1998, Transplantation.

[34]  A. Haeberli,et al.  Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. , 1996, The Journal of laboratory and clinical medicine.

[35]  J. Whitworth,et al.  Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[36]  D. Di Landro,et al.  Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. , 1995, Transplantation.

[37]  H. Büller,et al.  IMPAIRED FIBRINOLYSIS IN CYCLOSPORINE‐TREATED RENAL TRANSPLANT PATIENTS ANALYSIS OF THE DEFECT AND BENEFICIAL EFFECT OF FISH‐OIL , 1992, Transplantation.

[38]  H. Ohlin,et al.  Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. , 1987, Thrombosis research.

[39]  P. Morris,et al.  Deep venous thrombosis after renal transplantation. , 1987, Transplantation proceedings.

[40]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[41]  I. Martinelli.  von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. , 2005, Seminars in hematology.

[42]  A. Irish,et al.  Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  The 12th Report of the Human Renal Transplant Registry. Prepared by the Advisory Committee to the Renal Transplant Registry. , 1975, JAMA.